๐ PRO: This Week in Visuals
AMZN LLY NVO MRK DIS PEP PLTR LRLCY QCOM AMD ARM AMGN PFE UBER FI SPOT PYPL RACE CMG FTNT MDLZ GSK RBLX F YUM TTWO EA HSY PINS EXPE AFRM SNAP ALGN NYT MTCH PTON
Welcome to the Saturday PRO edition of How They Make Money.
Over 180,000 subscribers turn to us for business and investment insights.
In case you missed it:
๐ง Free members get our Friday articles and sneak peeks.
๐ Premium members receive monthly reports with 200+ companies visualized, one extra weekly article, and access to our archive.
๐ผ PRO members enjoy everything in Premium, plus our Saturday timely coverage of the most important earnings of the past week.
Today at a glance:
โ๏ธ Amazon: Capacity Limits
๐ Eli Lilly: Supply Scaling With Demand
๐ฉ๐ฐ Novo Nordisk: Strong GLP-1 Growth
๐ฆ Merck: Gardasil Pause
๐ฐ Disney: Box Office Boost
๐ฅค PepsiCo: Consumer Shifts
๐ต๏ธ Palantir: Astounding AI Demand
๐ L'Orรฉal: China Weighs on Growth
๐ฒ Qualcomm: Strong Finish
โ๏ธ AMD: High Expectations
๐ฑ ARM: AI Growth Continues
๐งฌ Amgen: Obesity Pipeline in Focus
๐ Pfizer: Cost Cuts & Covid Stability
๐ Uber: Strong Growth, Muted Outlook
๐ณ Fiserv: Clover Powers Growth
๐ง Spotify: First Annual Profit
๐ณ Paypal: Checkout & Venmo Focus
๐๏ธ Ferrari: Accelerating Profitability
๐ฏ Chipotle: Expansion Continues
๐ Fortinet: Firewall Refresh Ahead
๐ช Mondelez: Cocoa Costs Bite
๐ GSK: Raised 2031 Outlook
๐พ Roblox: Bookings Growth Slows
๐ Ford: Cost Cuts Ahead
๐ฎ YUM Brands: Taco Bell Leads Again
๐ฎ Take-Two: Big Titles Ahead
โฝ Electronic Arts: Sports Slump Hits Hard
๐ซ Hershey: Commodity Hedging
๐ Pinterest: First Billion-Dollar Quarter
โ๏ธ Expedia: Holiday Surge
๐ Affirm: Profit Ahead
๐ป Snap: Nearly Breakeven
๐ฆท Align: Soft Guidance
๐๏ธ New York Times: Outlook Comes Short
๐ฅ Match Group: New CEO, Same Challenges
๐ฒ Peloton: Subscribers Decline
1. โ๏ธ Amazon: Capacity Limits
Amazon saw revenue grow 10% Y/Y to $187.8 billion ($0.5 billion beat), and EPS was $1.86 ($0.38 beat). Operating income surged 61% to a record $21.2 billion, driven by efficiency gains and cloud profits. AWS revenue grew 19% to $28.8 billion, maintaining steady growth but facing capacity constraints due to chip supply and power availability, which may ease in the second half of 2025.
Despite strong results, Q1 guidance disappointed, with revenue projected at $151 to $155.5 billion( $158.6 billion expected) and operating income guidance of $14 to $18 billion ($18.4 billion expected). Management cited foreign exchange headwinds ($2.1 billion impact), a leap-year comparison, and infrastructure investments as key factors.
Amazon is set to investย overย $100 billionย in 2025 primarily in AI, custom chips, and data centers to meet soaring demand. While CEO Andy Jassy described Amazon as an โAI supermarket,โ near-term concerns about cloud growth and margins weighed on investor sentiment. However, Amazon has the balance sheet and operating cash flow ($116 billion in FY24) to fund its growth initiatives.
Next week, weโll dive deeper into the report, visualizing market share shifts in cloud infrastructure and advertising. Stay tuned!
2. ๐ Eli Lilly: Supply Scaling With Demand
Eli Lillyโs revenue surged 45% Y/Y to $13.5 billion ($100 million beat), driven by Mounjaro sales reaching $3.5 billion and Zepbound at $1.9 billion, both in line with pre-announced figures. While sales fell short of original expectations last quarter, FY25 guidance of $58-61 billion (+32% Y/Y) reassured investors. Management emphasized manufacturing expansion, with a 60% increase in GLP-1 supply expected in H1 2025 to support growing demand. The removal of Mounjaro and Zepbound from the FDAโs shortage list will also curb compounded alternatives, further solidifying Lillyโs market position.
With regulatory approvals for Kisunla and Ebglyss, expanded global launches for Mounjaro, and ongoing payer negotiations for Zepbound reimbursement, Lilly continues to strengthen its obesity and diabetes portfolio. Management remains bullish on the long-term growth runway, with further capacity investments needed to meet demand. The next key catalyst will be late-stage data for Orforglipron, Lillyโs oral obesity drug, expected mid-year.